TauroPharm
Private Company
Funding information not available
Overview
TauroPharm is a commercial-stage German biotech/medtech company focused on infection prevention for indwelling medical devices. Its technology platform is based on taurolidine, a broad-spectrum antimicrobial agent, formulated into lock solutions for catheters and pacemakers. With products recommended in several European clinical guidelines and a distribution network spanning over 50 countries, the company has established a niche in the prophylactic antimicrobial device market. TauroPharm operates as a private entity, generating revenue through its commercial product portfolio and continuously optimizing its formulations based on clinical feedback.
Technology Platform
Taurolidine-based antimicrobial lock solutions. Platform combines the broad-spectrum, non-antibiotic agent taurolidine with anticoagulants (citrate, heparin) and/or thrombolytics (urokinase) to create synergistic formulas that prevent both infections and occlusions in indwelling medical devices.
Opportunities
Risk Factors
Competitive Landscape
TauroPharm competes in the niche market of antimicrobial catheter lock solutions. Competitors include other companies offering taurolidine-based locks, antibiotic lock solutions (e.g., with minocycline/EDTA), and standard, non-antimicrobial heparin locks. Its differentiation lies in its specific dual-action formulations, strong guideline endorsements, and focused expertise in the taurolidine platform for both CVADs and CIEDs.